CF602 is a novel A3AR allosteric modulator that enhances the receptor activity in the presence of the native ligand. The molecule is characterized by high selectivity at the A3AR and is capable to avoid receptor desensitization, thus magnifying the agonist activity at low doses.
The activity of CF602 was examined in experimental animal models of arthritic diseases. Oral administration of CF602 induced an impressive anti-inflammatory effect, manifested by a decrease in the disease signs and symptoms.
Mechanism of Action
CF602 induces down-regulation of the PI3K-PKB/Akt-NF-kB signaling pathway in the inflammatory cells.